全球艱難梭菌感染治療市場：按藥物類型（萬古黴素、甲硝唑、非達黴素等）、給藥途徑、分銷渠道、地區 - 規模、份額、前景、機會分析，2023-2030 年

艱難梭菌可產生革蘭氏陽性菌，是一種厭氧毒素，通過糞口途徑傳播。 艱難梭菌感染的嚴重感染可導致水樣腹瀉、腹部絞痛、劇烈疼痛、脫水、心跳加快、白細胞計數升高、噁心和腎功能衰竭。 艱難梭菌感染可在抗生素治療期間發生或由醫療保健相關感染引起，臨床表現從無症狀感染到水樣腹瀉、結腸炎和結腸穿孔等嚴重並發症不等。 只有少數藥物如甲硝唑、非多黴素和萬古黴素可用於治療艱難梭菌感染。 如果有嚴重的腹壁疼痛或中毒性巨結腸，患者會接受手術切除感染區域。 這種疾病的高患病率和新興國家偶爾爆發的疾病預計將推動艱難梭菌感染治療市場的增長。 然而，頭孢菌素類和氟奎諾酮類等廣譜抗生素替代療法將阻礙艱難梭菌感染治療市場的增長。

市場動態

在預測期內，一些政府和非政府組織開展的提高認識活動預計將在推動全球艱難梭菌感染治療市場的增長方面發揮關鍵作用。 例如，2020 年 12 月，由非營利性全國性艱難梭菌宣傳組織 Peggy Lillis Foundation 發起，覆蓋超過 250,000 名美國人以傳播對艱難梭菌的認識。宣布其目標已實現。 2019 年，該組織發起了“See C.diff”以紀念艱難梭菌（Clostridium difficile）宣傳活動，並惠及了約 80,000 人。

此外，在 2021 年 3 月，Peggy Lilith Foundation 是一家在全國范圍內開展艱難梭菌意識提升活動的非營利性公司，將由 Ferring 製藥公司支持艱難梭菌感染患者。□與 Pharmaceuticals 合作. Peggy Lilith Foundation 和 Ferring Pharmaceuticals 之間的合作夥伴關係通過新的讚助來幫助患有艱難梭菌感染的患者，以資助新的和現有的患者宣傳工作。

此外，2021 年 12 月 4 日，Peggy Lillis 基金會宣布其在美國開展的艱難梭菌宣傳活動已惠及超過 100 萬人。

這項研究的主要特點

• 本報告對全球艱難梭菌傳染病市場進行了深入分析，結合以 2022 年為基準年的預測期（2023-2030 年）的市場規模為 8.934 億美元。顯示年增長率 (複合年增長率 7.1%)。
• 它還闡明了各個細分市場的潛在創收機會，並描述了該市場具有吸引力的投資建議矩陣。
• 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
• 本文根據以下參數介紹了全球艱難梭菌感染市場的主要參與者——公司亮點、產品組合、主要亮點、財務業績、本研究的策略主要公司包括 Novartis AG、Baxter、ANI Pharmaceuticals, Inc.、Mylan N.V.、Akorn、Sun Pharmaceutical Industries Ltd.、Merck & Co., Inc.、B. Braun Medical Inc.、Teva Pharmaceutical Industries Ltd.、Hikma Pharmaceutical PLC、Perrigo Pharmaceutical.、Apotex Inc.、AbbVie Inc.、Ferring Pharmaceuticals、Fresenius Kabi USA.、Pfizer Inc.、Strides Pharma Science Limited.、Sanofi.、AstraZeneca.、Eli Lilly and Company.、Actelion Pharmaceuticals Ltd. 和 Astellas Pharma
• 這份報告中的見解將幫助營銷人員和企業高管就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 《全球艱難梭菌傳染病市場報告》面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球艱難梭菌感染市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫

第二章市場範圍

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 按藥物類型劃分的市場概況
  • 按給藥途徑劃分的市場概況
  • 市場概況：按分銷渠道
  • 市場概況：按地區
• 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場吸引力分析
  • 市場機會
• 產品發布
• 合併/收購/聯合研究
• 監管準則和合規性
• 主要發展
• 政府舉措
• 害蟲分析
• 技術概況
• 對 PORTER 的分析
• 價格分析

第 4 章艱難梭菌感染藥物的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 經濟影響
• COVID-19 流行病學
• 對供需的影響

第 5 章：按藥物類型分列的艱難梭菌感染全球藥物市場：2017-2030

• 萬古黴素
• 甲硝唑
• 非達黴素
• 其他（仿製藥等）

第 6 章：按給藥途徑分列的全球艱難梭菌藥物市場，2017-2030

• 口語
• 可注射

第 7 章。全球艱難梭菌藥物市場：按分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 8 章。全球艱難梭菌藥物市場：按地區劃分，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第9章競爭格局

• Novartis AG
• Baxter
• ANI Pharmaceuticals, Inc.
• Mylan N.V.
• Akorn
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Braun Medical Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceutical PLC
• Perrigo Pharmaceutical
• Apotex Inc.
• AbbVie Inc.
• Ferring Pharmaceuticals
• Fresenius Kabi USA.
• Pfizer Inc.
• Strides Pharma Science Limited
• Sanofi
• AstraZeneca
• Eli Lilly and Company
• Actelion Pharmaceuticals Ltd.
• Astellas Pharma

第 10 章

• 調查方法
• 關於出版商

Clostridiodes Difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through the fecal-oral route. The severe infection of clostridium difficile infection is watery diarrhea, abdominal cramping, and pain, which may be severe, dehydration, rapid heart rate, increased white blood cell count, nausea, and kidney failure. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare-associated infection with clinical manifestations ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. Limited types of drugs such as metronidazole, fidoxamicin, and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in the abdominal wall, patients undergo surgery for the removal of the infected portion. The high prevalence of this disease and occasional disease outbreaks in emerging economies is expected to drive the growth of clostridioides difficile infection treatment market. However, alternative therapy for a broad-spectrum antibiotic such as cephalosporins or fluoroquinolone will hinder the growth of Clostridioides difficile Infection treatment market .

Market Dynamics

Increasing awareness campaigns by several government and non-government organizations are expected to play important role in driving the growth of the global clostridioides difficile infection treatment market growth for the forecast period. For instance, in December 2020, launched by Peggy Lillis Foundation, a nationwide Clostridium difficile awareness organizer, a not-for-profit corporation, announced that they have acomplished their objective by reaching more than 250,000 Americans to spread awareness regarding Clostridium Difficile. The organization launched the 'See C. diff' to commemorate C. diff (Clostridium Difficile) awareness campaign in 2019, and reached about 80,000 people.

Furthermore, in March 2021, Peggy Lillis Foundation, a nationwide Clostridium difficile awareness organizer and a not-for-profit corporation, partnered with Ferring Pharmaceuticals, pharmaceutical company, to help and support patients with clostridioides difficile infection. The partnership between Peggy Lillis Foundation and Ferring Pharmaceuticals helped patients suffering from clostridioides difficile infection through new sponsorship to fund new and existing patient advocacy initiatives.

Moreover, on December 4, 2021, the Peggy Lillis Foundation, announced that they have reached more than 1 million people during C. diff awareness campaign in U. S.

Key features of the study:

• This report provides in-depth analysis of the global clostridioides difficile infection market, and provides market size (US$ 893.4 Million) and compound annual growth rate (CAGR 7.1 %) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global clostridioides difficile infection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Novartis AG, Baxter, ANI Pharmaceuticals, Inc., Mylan N.V., Akorn, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., B. Braun Medical Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Perrigo Pharmaceutical., Apotex Inc., AbbVie Inc., Ferring Pharmaceuticals, Fresenius Kabi USA., Pfizer Inc., Strides Pharma Science Limited., Sanofi., AstraZeneca., Eli Lilly and Company., Actelion Pharmaceuticals Ltd., and Astellas Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global clostridioides difficile infection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clostridioides difficile infection market

Detailed Segmentation:

• Global Clostridioides Difficile Infection Treatment Market, By Drug Type:
  • Vancomycin
  • Metronidazole
  • Fidaxomicin
  • Others (late phase drugs, etc.)
• Global Clostridioides Difficile Infection Treatment Market, By Route of Administration:
  • Oral
  • Injectable
• Global Clostridioides Difficile Infection Treatment Market By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Clostridioides Difficile Infection Treatment Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Novartis AG*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Baxter
  • ANI Pharmaceuticals, Inc.
  • Mylan N.V.
  • Akorn
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • B.Braun Medical Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceutical PLC
  • Perrigo Pharmaceutical
  • Apotex Inc.
  • AbbVie Inc.,
  • Ferring Pharmaceuticals
  • Fresenius Kabi USA.
  • Pfizer Inc.,
  • Strides Pharma Science Limited.
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company
  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
• Product Launches
• Merger, Acquisition, Collaborations
• Regulatory Guideline and Compliances
• Key Developments
• Government Initiatives
• PEST Analysis
• Technology Landscape
• PORTER's Analysis
• Pricing Analysis

4. Global Clostridioides Difficile Infection Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Clostridioides Difficile Infection Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Vancomycin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Metronidazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Fidaxomicin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (late phase drugs, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Clostridioides Difficile Infection Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Clostridioides Difficile Infection Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Clostridioides Difficile Infection Treatment Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Baxter
• ANI Pharmaceuticals, Inc.
• Mylan N.V.
• Akorn
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Braun Medical Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceutical PLC
• Perrigo Pharmaceutical
• Apotex Inc.
• AbbVie Inc.
• Ferring Pharmaceuticals
• Fresenius Kabi USA.
• Pfizer Inc.
• Strides Pharma Science Limited
• Sanofi
• AstraZeneca
• Eli Lilly and Company
• Actelion Pharmaceuticals Ltd.
• Astellas Pharma

10. Section

• Research Methodology
• About Us